Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial

Curatolo, Paolo; Franz, David; Lawson, John; Yapici, ZÜHAL; Ikeda, Hiroko; Polster, Tilman; Nabbout, Rima; de Vries, Petrus; Dlugos, Dennis; Fan, Jenna; Ridolfi, Antonia; Pelov, Diana; Voi, Maurizio; French, Jacqueline

doi:10.1016/s2352-4642(18)30099-3

Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial

Curatolo P., Franz D. N., Lawson J. A., Yapici Z., Ikeda H., Polster T., ...Daha Fazla

LANCET CHILD & ADOLESCENT HEALTH, cilt.2, sa.7, ss.495-504, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 2 Sayı: 7
Basım Tarihi: 2018
Doi Numarası: 10.1016/s2352-4642(18)30099-3
Dergi Adı: LANCET CHILD & ADOLESCENT HEALTH
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.495-504
İstanbul Üniversitesi Adresli: Evet

Özet

Background Epilepsy occurs in 70-90% of patients with tuberous sclerosis complex. We aimed to assess the efficacy and safety of adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex in paediatric patients enrolled in the EXIST-3 trial, a double-blind, placebo-controlled, randomised, phase 3 study.